<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477900</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477900</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Grand round</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tomov</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477900">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lazarchick</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477900">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Self</surname><given-names>SE</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477900">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bruner</surname><given-names>ET</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477900">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Budisavljevic</surname><given-names>MN</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477900">1</xref>
<xref ref-type="aff" rid="aff3-0961203313477900">3</xref>
<xref ref-type="corresp" rid="corresp1-0961203313477900"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313477900"><label>1</label>Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA</aff>
<aff id="aff2-0961203313477900"><label>2</label>Pathology and Laboratory Medicine Medical University of South Carolina, Charleston, South Carolina, USA</aff>
<aff id="aff3-0961203313477900"><label>3</label>Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA</aff>
<author-notes>
<corresp id="corresp1-0961203313477900">Milos N. Budisavljevic, Nephrology Division, Medical University of South Carolina, 171 Ashley Ave., Charleston, SC, 29425, USA. Email: <email>budisamn@musc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>504</fpage>
<lpage>509</lpage>
<history>
<date date-type="received"><day>20</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>17</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We present the case of a 19 year-old Caucasian female with history of systemic lupus erythematosus (SLE) and normal baseline kidney function who developed severe acute renal failure following treatment of thrombocytopenia with the thrombopoietic agent romiplostim. Percutaneous kidney biopsy revealed thrombotic microangiopathy (TMA) without immune complex lupus glomerulonephritis. We discuss pathogenesis and differential diagnosis of TMA in patients with SLE and raise concerns regarding the use of thrombopoietic agents in such patients. Based on favorable long-term outcome in our case aggressive treatment and in particular prolonged use of plasma exchange in these patients are advocated.</p>
</abstract>
<kwd-group>
<kwd>Thrombotic microangiopathy</kwd>
<kwd>antiphospholipid syndrome</kwd>
<kwd>thrombotic thrombocytopenic purpura</kwd>
<kwd>romiplostim</kwd>
<kwd>acute renal failure</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>plasma exchange</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313477900" sec-type="cases"><title>Case presentation</title>
<p>A 19 year-old Caucasian female with normal baseline kidney function (serum creatinine concentration 0.9 mg/dl) was admitted to the Nephrology service at our hospital from an outside emergency room for acute kidney injury. Her presenting complaint was a 3-day history of left flank pain, nausea, and low-grade fever.</p>
<p>She had systemic lupus erythematosus (SLE) for 8 years, currently treated with mycophenolate mofetil 1000 mg twice daily and hydroxychloroquine 200 mg daily. Nine months prior to presentation, her first and only pregnancy ended in a spontaneous abortion at 11 weeks of gestation. At that time her anti-cardiolipin (phospholipid antibodies), anti-β2-glycoprotein I antibodies and Dilute Russell Viper Venom Time (DRVVT) were negative. Magnetic resonance imaging and computed tomography performed for right upper quadrant pain 1.5 years prior to presentation revealed small hypodensities in the spleen and right kidney consistent with small infarcts.</p>
<p>She also had a history of thrombocytopenia for about 4 years with an average platelet count of 30−40 K/CUM, which had been treated ineffectively over the previous 18 months with rituximab (three doses) and intravenous immunoglobulin (one dose). For this reason she was started on the new second-generation thrombopoietic agent romiplostim (Nplate). She received six weekly doses, the last one 10 days prior to presentation.</p>
<p>On physical examination the patient was a well-nourished Caucasian female with a temperature of 99.5 °F, heart rate of 105 bpm, blood pressure of 140/101 mmHg, and weight of 67 kg. Her heart and lung examinations were unremarkable. The abdomen was soft, and there was left flank tenderness on palpation. There was no edema, petechial rash or cyanosis, and peripheral pulses were normal.</p>
<p>Laboratory values at presentation are included here, with reference ranges in parentheses: peripheral white blood cell count 6.3 K/CUM (4.8–10.8 K/CUM), hemoglobin 6.5 g/dl (12–16 g/dl), hematocrit 19.4% (37–47%), platelet count 60 K/CUM (140−440 K/CUM), blood urea nitrogen 30 mg/dl (8–20 mg/dl), creatinine 4.4 mg/dl (0.4–1.0 mg/dl), LDH 292 IU/l (100–240 IU/l), haptoglobin 112 mg/dl (36–195 mg/dl), fibrinogen 482 mg/dl (231–486 mg/dl), and D-dimer 4.78 (&lt;0.43). Serum electrolytes, bilirubin, glucose and liver enzymes were within normal limits. Direct Coombs test, anti-glomerular basement membrane antibodies, anti-neutrophil cytoplasmic antibodies, human immunodeficiency virus, and β-human chorionic gonadotropin were negative. The peripheral blood smear showed normochromic, normocytic RBCs with minimal anisocytosis and rare polychromatic forms. RBC fragments were not seen. The WBC differential was 58% neutrophils, 13% monocytes, 26% lymphocytes, and 3% eosinophils. Platelets were decreased with an occasional large form noted.</p>
<p>Urinalysis revealed pH 5.5, specific gravity 1.008, protein 30 mg/dl, ketones 10 mg/dl, and 2 RBC/hpf with no casts. Random urine protein:creatinine ratio was about 1 g/g. The remaining relevant laboratory results on the day of presentation and 6–8 months earlier are shown in <xref ref-type="table" rid="table1-0961203313477900">Table 1</xref> and demonstrated low-titer lupus anticoagulants.
<table-wrap id="table1-0961203313477900" position="float"><label>Table 1</label><caption><p>Laboratory Data</p></caption>
<graphic alternate-form-of="table1-0961203313477900" xlink:href="10.1177_0961203313477900-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Test (reference range)</th>
<th>At presentation</th>
<th>Earlier</th>
</tr></thead>
<tbody align="left">
<tr>
<td>C3 complement (88–201 mg/dl)</td>
<td>89.2</td>
<td>73.6 <sup><xref ref-type="table-fn" rid="table-fn1-0961203313477900">a</xref></sup></td>
</tr>
<tr>
<td>C4 complement (16–47 mg/dl)</td>
<td>30.9</td>
<td>14.1 <sup><xref ref-type="table-fn" rid="table-fn1-0961203313477900">a</xref></sup></td>
</tr>
<tr>
<td>Anti dsDNA (≤30.0 IU/ml)</td>
<td>263.1</td>
<td>221.4</td>
</tr>
<tr>
<td>PT (sec)</td>
<td>15.3</td>
<td>n/a</td>
</tr>
<tr>
<td>aPTT (23.3–35.7 sec)</td>
<td>41.3</td>
<td>40.3</td>
</tr>
<tr>
<td>Mixing study</td>
<td>PT and aPTTcorrected</td>
<td>n/a</td>
</tr>
<tr>
<td>Cardiolipin antibody IgG</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>Cardiolipin antibody IgM</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Cardiolipin antibody IgA</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>β2 glycoprotein I antibody IgG (0–20)</td>
<td>&lt; 1</td>
<td>0</td>
</tr>
<tr>
<td>β2 glycoprotein I antibody IgM (0–20)</td>
<td>&lt; 1</td>
<td>0</td>
</tr>
<tr>
<td>DRVVT screen (33–44)</td>
<td>73</td>
<td>48</td>
</tr>
<tr>
<td>DRVVT confirmation (≤ 1.34)</td>
<td>1.54</td>
<td>n/a</td>
</tr>
<tr>
<td>Lupus anticoagulants screen</td>
<td>positive</td>
<td>positive</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313477900"><label>a</label><p>Earlier reference values for C3 and C4 complement were 70–206 mg/dl and 11−61 mg/dl, respectively</p></fn>
<fn id="table-fn2-0961203313477900"><p>aPTT: activate partial Thromboplastin time; DRVVT: Dilute Russell Viper Venom Time; PT: Prothrombin time</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Because the etiology of acute renal failure was unclear, percutaneous kidney biopsy was performed on the second hospital day. Twenty-five non-sclerotic glomeruli were identified by light microscopy (<xref ref-type="fig" rid="fig1-0961203313477900">Figures 1a</xref> and <xref ref-type="fig" rid="fig1-0961203313477900">1b</xref>). Some of the glomeruli contained fibrous crescents, but no proliferative changes were observed in the endocapillary or extracapillary areas. A single glomerulus contained fibrin deposition within the capillary lumen. Several arterioles showed endothelial swelling and fibrinoid necrosis characteristic of thrombotic microangiopathy (TMA). No significant interstitial fibrosis or inflammation was present. Tubules contained both protein and red cell casts. The one artery present lacked vasculitis and was otherwise unremarkable. Four glomeruli examined by direct immunofluorescence exhibited trace mesangial deposition of IgM. IgA was present within protein casts, and the specimen was negative for deposition of IgG, fibrin, C3, C1q, kappa, and lambda light chains.
<fig id="fig1-0961203313477900" position="float"><label>Figure 1</label><caption><p>a and 1b. Light microscopy of the patient’s biopsy at the time of presentation. The glomerulus on the right contains fibrin thrombi within the capillary tuft. Arterioles above each glomerulus show endothelial swelling and fibrinoid necrosis, characteristic of TMA. (1 a) H&amp;E staining × 400; (1 b) Masson’s trichrome stain × 400). <xref ref-type="fig" rid="fig1-0961203313477900">Figure 1c</xref>. electron micrograph of the same sample demonstrates a swollen glomerular endothelial cell with widening of the subendothelial space with resultant narrowing of the capillary lumen.</p></caption><graphic xlink:href="10.1177_0961203313477900-fig1.tif"/>
</fig></p>
<p>One glomerulus was examined by electron microscopy (<xref ref-type="fig" rid="fig1-0961203313477900">Figure 1c</xref>). The visceral epithelial cell foot processes were partially effaced. No electron-dense deposits compatible with immune complexes were seen either along the glomerular basement membrane or within the mesangium. The endothelial cells showed diffuse swelling with widening of the subendothelial space. No tubuloreticular inclusions were seen. The basement membrane was of normal thickness and contour. The pathologic diagnosis of TMA without immune complex lupus glomerulonephritis was made.</p>
<p>This hospital course is depicted in <xref ref-type="fig" rid="fig2-0961203313477900">Figure 2</xref>. Following the renal biopsy, further diagnostic testing revealed that ADAMTS13 activity was normal (76%) and an ADAMTS13 inhibitor was not present. The patient was aggressively treated with daily plasmapheresis initiated on Hospital Day 3, anticoagulation (initially intravenous heparin, then oral warfarin), corticosteroids (initially intravenous methylprednisolone, then oral prednisone), and monthly cyclophosphamide infusions. Her serum creatinine concentration peaked at 6.7 mg/dl on Day 5. She developed dyspnea secondary to extracellular fluid volume overload, and four hemodialysis sessions were performed.
<fig id="fig2-0961203313477900" position="float"><label>Figure 2</label><caption><p>Serum creatinine levels and treatment course after diagnosis of thrombotic microangiopathy by kidney biopsy.</p>
<p>Bx: kidney biopsy; PE: plasma exchange; QD: daily; TIW: thrice weekly.</p></caption><graphic xlink:href="10.1177_0961203313477900-fig2.tif"/>
</fig></p>
<p>Upon discharge from the hospital on Day 39, she was free from the need of dialysis with serum creatinine concentrations of 1.9 mg/dl and 1.4 mg/dl 5 months later. She then received four additional infusions of intravenous cyclophosphamide for a total of six doses. Several months after discharge from the hospital, she discontinued warfarin therapy on her own. At most recent follow-up more than 3.5 years later, her serum creatinine concentration was 1.2 mg/dl with no activity in the urinary sediment and proteinuria of 300 mg per day.</p>
</sec>
<sec id="sec2-0961203313477900" sec-type="discussion"><title>Discussion</title>
<p>We describe a young woman with a long history of SLE who presented with acute renal failure, anemia, and thrombocytopenia without evidence of intravascular hemolysis. Renal biopsy revealed TMA without WHO/RPA immune complex glomerulonephritis. TMA is a pathologic finding associated with variety of clinical syndromes. Pathogenetically it can be classified into thrombotic thrombocytopenic purpura (TTP), which is characterized by Von Willebrand factor protease (ADAMTS13) deficiency, and hemolytic uremic syndrome (HUS), which results from damage to the glomerular endothelium.<sup><xref ref-type="bibr" rid="bibr1-0961203313477900">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203313477900">2</xref></sup> Endothelial injury may be caused by infectious agents (Shiga toxin, neuraminidase producing bacteria, human immunodeficiency virus), genetically or immunologically mediated abnormalities of the complement system, pregnancy, radiation injury, hematopoietic stem cell transplantation, systemic diseases (antiphospholipid syndrome, scleroderma, malignant hypertension, malignancy), or drugs.<sup><xref ref-type="bibr" rid="bibr3-0961203313477900">3</xref><xref ref-type="bibr" rid="bibr4-0961203313477900"/>–<xref ref-type="bibr" rid="bibr5-0961203313477900">5</xref></sup> Our patient did not have evidence of malignant hypertension, scleroderma, or treatment with medications known to be associated with TMA. Tests for human immunodeficiency, cytomegalo- and hepatitis C viruses<sup><xref ref-type="bibr" rid="bibr6-0961203313477900">6</xref></sup> were negative. Furthermore, we found no clinical or laboratory evidence of any acute bacterial infection,<sup><xref ref-type="bibr" rid="bibr7-0961203313477900">7</xref></sup> in particular caused by <italic>Escherichia coli, Shigella or Streptococcus pneumoniae</italic>. Although we did not perform full testing, the patient’s age at presentation and absence of relapse after almost 4 years of follow-up strongly argue against complement-mediated atypical HUS as the etiology of her TMA. Hence, her TMA in the setting of SLE might have been the result of one of the three following scenarios.</p>
<sec id="sec3-0961203313477900"><title>Development of TTP in a patient with pre-existing SLE</title>
<p>Two distinct pathologic processes, TTP and SLE, rarely may occur in the same patient.<sup><xref ref-type="bibr" rid="bibr8-0961203313477900">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203313477900">9</xref></sup> Clinical features of TTP including anemia, thrombocytopenia, and neurological symptoms occur in patients with SLE, and some patients with TTP develop SLE-like illnesses, arguing for co-existence of these two conditions. In both TTP and SLE, most patients are young women, with a relative increased incidence among African Americans.<sup><xref ref-type="bibr" rid="bibr10-0961203313477900">10</xref></sup> The possibility for misdiagnosis is exacerbated further by the fact that 70% of patients with TTP with severe ADAMTS13 deficiency (less than 5% activity) have positive ANA (titer greater than 1:80), and 10% have anti-double-stranded-DNA antibodies.<sup><xref ref-type="bibr" rid="bibr11-0961203313477900">11</xref></sup> Similarly, 30% of patients with SLE and 24% of patients with the antiphospholipid antibody syndrome and thromboembolic complications have anti-ADAMTS13 antibodies. However, none of these antibodies was inhibitory and ADAMTS13 activity remained greater than 22%.<sup><xref ref-type="bibr" rid="bibr12-0961203313477900">12</xref></sup></p>
<p>In 2009, the Oklahoma TTP registry consisted of 335 patients with the clinical diagnosis of TTP or HUS. Of these, 29 patients were given the clinical diagnoses of TTP and SLE, but the co-existence of these was confirmed by ADAMTS13 activity of less than 10% in only two patients (7%).<sup><xref ref-type="bibr" rid="bibr13-0961203313477900">13</xref></sup> Likewise, McDonald identified only one case (5%) of SLE among 19 children and adolescents with severe ADAMTS13 deficiency.<sup><xref ref-type="bibr" rid="bibr14-0961203313477900">14</xref></sup> We would thus agree with the suggestion elegantly argued by Hunt that the occurrence of TTP and SLE in the same patient has been exaggerated in the literature, due to inclusion of TTP-like or SLE-like conditions.<sup><xref ref-type="bibr" rid="bibr15-0961203313477900">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203313477900">16</xref></sup> On the other hand, an interesting series of eight children with TTP and severe ADAMTS13 deficiency was recently described. During 8.5 years of follow-up, all children developed systemic autoimmunity, and six developed immune complex lupus nephritis with antiphospholipid antibodies.<sup><xref ref-type="bibr" rid="bibr17-0961203313477900">17</xref></sup> Whether severe ADAMTS13 deficiency predisposes children to autoimmune disease requires further investigation.</p>
<p>The absence of intravascular hemolysis and the activity of ADAMTS13 within normal range exclude TTP in our patient.</p>
</sec>
<sec id="sec4-0961203313477900"><title>Development of renal TMA in the absence of anti-phospholipid antibodies in a patient with pre-existing SLE</title>
<p>Vascular lesions are an integral part of SLE, and TMA can be seen in 0.6–2.7% of kidney biopsies performed in patients with SLE.<sup><xref ref-type="bibr" rid="bibr18-0961203313477900">18</xref><xref ref-type="bibr" rid="bibr19-0961203313477900"/><xref ref-type="bibr" rid="bibr20-0961203313477900"/>–<xref ref-type="bibr" rid="bibr21-0961203313477900">21</xref></sup> Renal TMA in patients with SLE is almost always associated with immune complex SLE glomerulonephritis<sup><xref ref-type="bibr" rid="bibr22-0961203313477900">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477900">23</xref></sup> and/or serologic evidence of antiphospholipid syndrome (anti-cardiolipin, anti-beta 2 glycoprotein 1, or positive testing for lupus anticoagulants (Sta-Clot and Dilute Russell Viper Venom Time)). Most of the older studies lack data on the presence of antiphospholipid syndrome. After review of the literature we found that, of 886 kidney biopsies from patients with SLE, only three (0.3%) contained TMA without immune complex glomerulonephritis or positive antiphospholipid serology or lupus anticoagulants.</p>
<p>Absence of WHO/RPA immune complex lupus glomerulonephritis and low titer of lupus anticoagulants makes this scenario in our patient unlikely.</p>
</sec>
<sec id="sec5-0961203313477900"><title>Development of renal TMA as manifestation of acute antiphospholipid nephropathy in a patient with pre-existing SLE</title>
<p>Antiphospholipid syndrome nephropathy, either acute or chronic, can occur in patients with SLE and is statistically associated with presence of lupus anticoagulant but not cardiolipin antibodies.<sup><xref ref-type="bibr" rid="bibr24-0961203313477900">24</xref></sup> TMA is a hallmark of acute antiphospholipid syndrome nephropathy and was found in nine of 114 (8%) of kidney biopsies performed in patients with SLE in France.<sup>25</sup> In only one of these biopsies was simultaneous presence of immune complex SLE glomerulonephritis not found. Similarly, Farrugia evaluated data from 478 biopsies of SLE nephritis patients at Mayo Clinic. Thirty-three of 478 patients (6.9%) had lupus anticoagulants. TMA was found in 15% of these patients (five of 33), three of whom lacked immune complex SLE glomerulonephritis.<sup><xref ref-type="bibr" rid="bibr26-0961203313477900">26</xref></sup> Therefore, as alluded to above, TMA in patients with SLE is rare in the absence of concomitant glomerulonephritis and usually indicates presence of antiphospholipid antibodies.<sup><xref ref-type="bibr" rid="bibr27-0961203313477900">27</xref></sup> The finding of TMA appears to worsen the prognosis.<sup><xref ref-type="bibr" rid="bibr22-0961203313477900">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477900">23</xref>,<xref ref-type="bibr" rid="bibr26-0961203313477900">26</xref>,<xref ref-type="bibr" rid="bibr28-0961203313477900">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313477900">29</xref></sup> Two aspects of antiphospholipid syndrome appear to be particularly associated with antiphospholipid syndrome nephropathy: history of arterial thrombi and obstetric complications.<sup><xref ref-type="bibr" rid="bibr24-0961203313477900">24</xref></sup> Our patient had early miscarriage and suspicious small infarcts in the spleen and kidney. Despite absence of antiphospholipid antibodies we cannot exclude that her TMA was a consequence of low-grade antiphospholipid syndrome. However, as indicated by Hu,<sup><xref ref-type="bibr" rid="bibr23-0961203313477900">23</xref></sup> many of such patients require the additional 'trigger' to develop TMA.</p>
<p>We believe that treatment with romiplostim was such a trigger in our patient. Although romiplostim had not been implicated in the development of TMA as yet in the medical literature, several lines of evidence support this claim in our case. The patient developed TMA shortly after initiation of treatment with this agent and experienced a favorable renal outcome compared with data from the literature. The minimal prolongations of her Prothrombin time (PT)/activate partial Thromboplastin time (aPTT) were consistent with the presence of a low-titer lupus anticoagulant, as judged by complete correction of both PT and aPTT by one part normal plasma to one part patient plasma mixing study. In summary, the absence of anti-phospholipid antibodies, a low-titer lupus anticoagulant, the pathologic findings on renal biopsy, the temporal relationship of the onset of her TMA shortly after starting romiplostim, and no evidence of relapse or development of any thromboembolic event on careful follow-up for almost 4 years after the initial episode despite absence of anticoagulation, all support our contention that romiplostim was the causative factor in the patient’s development of TMA. As an additional proof, renal TMA has recently been reported with another second-generation thrombopoietic agent, eltrombopag.<sup><xref ref-type="bibr" rid="bibr30-0961203313477900">30</xref></sup></p>
<p>Thrombotic events, including deep vein thrombosis, myocardial infarction, coronary stent thrombosis, septic thrombophlebitis, transient ischemic attack, and portal vein thrombosis have been described in patients treated with romiplostim<sup><xref ref-type="bibr" rid="bibr31-0961203313477900">31</xref><xref ref-type="bibr" rid="bibr32-0961203313477900"/><xref ref-type="bibr" rid="bibr33-0961203313477900"/><xref ref-type="bibr" rid="bibr34-0961203313477900"/>–<xref ref-type="bibr" rid="bibr35-0961203313477900">35</xref></sup> and occurred mostly in those with pre-existing thrombotic risk factors. In 76% of cases, thrombotic events were seen when platelet count was below 400 K/CUM. However, in pooled analysis of all studies, the incidence of these events did not differ from that of patients receiving placebo.<sup><xref ref-type="bibr" rid="bibr32-0961203313477900">32</xref>,<xref ref-type="bibr" rid="bibr35-0961203313477900">35</xref></sup></p>
<p>We do not have a clear explanation of how romiplostim or eltrombopag may cause TMA. In addition to increasing the number of platelets, endogenous thrombopoietin potentiates platelet activation to numerous agonists and enhances platelet degranulation, adhesion, and shear-mediated platelet activation.<sup><xref ref-type="bibr" rid="bibr36-0961203313477900">36</xref></sup> However, these activities may differ with second-generation of thrombopoietic agents.<sup><xref ref-type="bibr" rid="bibr37-0961203313477900">37</xref></sup></p>
<p>In summary, our case report and review of recent publications has several important points to convey. Despite reports in the literature, the occurrence of TTP in patients with SLE is rare. It should only be considered in cases where severe ADAMTS 13 deficiency (&lt; 10% activity) is confirmed. Renal TMA in patients with SLE is almost always associated with immune complex SLE glomerulonephritis. In those who do not display SLE glomerulonephritis, finding of TMA suggests antiphospholipid syndrome. Patients with SLE who present with unexplained acute kidney injury with bland urine sediment and normal serum complement levels warrant early kidney biopsy. In patients with thrombocytopenia, extensive work-up of prothrombotic risk should be undertaken before treatment with a thrombopoietic agent, in particular those with suspected or confirmed SLE. Romiplostim and eltrombopag may cause renal TMA in predisposed patients even when the clinical picture of a prothrombotic state is very subtle. Although it appears that discontinuation of romiplostim resulted in a favorable renal outcome in our patient, aggressive treatment of TMA should be employed as soon as possible. In particular we would advocate prolonged daily plasma exchange<sup><xref ref-type="bibr" rid="bibr23-0961203313477900">23</xref></sup> with fresh frozen plasma as a replacement fluid.</p>
</sec>
</sec>
</body>
<back>
<sec id="sec6-0961203313477900"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec7-0961203313477900"><title>Conflict of Interest Statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477900"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desch</surname><given-names>K</given-names></name><name><surname>Motto</surname><given-names>D</given-names></name></person-group>. <article-title>Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?</article-title> <source>J Am Soc Nephrol</source> <year>2007</year>; <volume>18</volume>: <fpage>2457</fpage>–<lpage>2460</lpage>.</citation></ref>
<ref id="bibr2-0961203313477900"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moake</surname><given-names>J</given-names></name></person-group>. <article-title>Thrombotic microangiopathies: Multimers, metalloprotease, and beyond</article-title>. <source>Clin Transl Sci</source> <year>2009</year>; <volume>2</volume>: <fpage>366</fpage>–<lpage>373</lpage>.</citation></ref>
<ref id="bibr3-0961203313477900"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Terrell</surname><given-names>DR</given-names></name><name><surname>Vesely</surname><given-names>SK</given-names></name><name><surname>Kremer Hovinga</surname><given-names>JA</given-names></name><name><surname>Lammle</surname><given-names>B</given-names></name></person-group>. <article-title>Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer</article-title>. <source>Presse Med</source> <year>2012</year>; <volume>41</volume>: <fpage>e177</fpage>–<lpage>e188</lpage>.</citation></ref>
<ref id="bibr4-0961203313477900"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keir</surname><given-names>L</given-names></name><name><surname>Coward</surname><given-names>RJ</given-names></name></person-group>. <article-title>Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy</article-title>. <source>Pediatr Nephrol</source> <year>2011</year>; <volume>26</volume>: <fpage>523</fpage>–<lpage>533</lpage>.</citation></ref>
<ref id="bibr5-0961203313477900"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>PJ</given-names></name><name><surname>Sipols</surname><given-names>JM</given-names></name><name><surname>George</surname><given-names>JN</given-names></name></person-group>. <article-title>Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome</article-title>. <source>Curr Opin Hematol</source> <year>2001</year>; <volume>8</volume>: <fpage>286</fpage>–<lpage>293</lpage>.</citation></ref>
<ref id="bibr6-0961203313477900"><label>6</label><citation citation-type="other"><comment>Baid-Agrawal S, Farris AB, 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. <italic>Kidney Int</italic> 2011; 80: 879–885</comment>.</citation></ref>
<ref id="bibr7-0961203313477900"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coppo</surname><given-names>P</given-names></name><name><surname>Adrie</surname><given-names>C</given-names></name><name><surname>Azoulay</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?</article-title> <source>Intensive Care Med</source> <year>2003</year>; <volume>29</volume>: <fpage>564</fpage>–<lpage>569</lpage>.</citation></ref>
<ref id="bibr8-0961203313477900"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname><given-names>WD</given-names></name><name><surname>Traum</surname><given-names>AZ</given-names></name><name><surname>Makar</surname><given-names>RS</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name></person-group>. <article-title>Case records of the Massachusetts General Hospital. Case 37–2010. A 16-year-old girl with confusion, anemia, and thrombocytopenia</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>363</volume>: <fpage>2352</fpage>–<lpage>2361</lpage>.</citation></ref>
<ref id="bibr9-0961203313477900"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knecht</surname><given-names>ME</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Scheiflinger</surname><given-names>F</given-names></name><name><surname>Trendelenburg</surname><given-names>M</given-names></name></person-group>. <article-title>A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13</article-title>. <source>Nephrol Dial Transplant</source> <year>2010</year>; <volume>25</volume>: <fpage>1720</fpage>–<lpage>1722</lpage>.</citation></ref>
<ref id="bibr10-0961203313477900"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Vesely</surname><given-names>SK</given-names></name><name><surname>James</surname><given-names>JA</given-names></name></person-group>. <article-title>Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus</article-title>. <source>South Med J</source> <year>2007</year>; <volume>100</volume>: <fpage>512</fpage>–<lpage>514</lpage>.</citation></ref>
<ref id="bibr11-0961203313477900"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coppo</surname><given-names>P</given-names></name><name><surname>Bengoufa</surname><given-names>D</given-names></name><name><surname>Veyradier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement</article-title>. <source>Medicine</source> <year>2004</year>; <volume>83</volume>: <fpage>233</fpage>–<lpage>244</lpage>.</citation></ref>
<ref id="bibr12-0961203313477900"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieger</surname><given-names>M</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Kremer Hovinga</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases</article-title>. <source>Blood</source> <year>2005</year>; <volume>106</volume>: <fpage>1262</fpage>–<lpage>1267</lpage>.</citation></ref>
<ref id="bibr13-0961203313477900"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terrell</surname><given-names>DR</given-names></name><name><surname>Vesely</surname><given-names>SK</given-names></name><name><surname>Hovinga</surname><given-names>JA</given-names></name><name><surname>Lammle</surname><given-names>B</given-names></name><name><surname>George</surname><given-names>JN</given-names></name></person-group>. <article-title>Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes</article-title>. <source>Am J Hematol</source> <year>2010</year>; <volume>85</volume>: <fpage>844</fpage>–<lpage>847</lpage>.</citation></ref>
<ref id="bibr14-0961203313477900"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>V</given-names></name><name><surname>Liesner</surname><given-names>R</given-names></name><name><surname>Grainger</surname><given-names>J</given-names></name><name><surname>Gattens</surname><given-names>M</given-names></name><name><surname>Machin</surname><given-names>SJ</given-names></name><name><surname>Scully</surname><given-names>M</given-names></name></person-group>. <article-title>Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: Clinical management and the use of ADAMTS 13 assays</article-title>. <source>Blood Coagul Fibrinolysis</source> <year>2010</year>; <volume>21</volume>: <fpage>245</fpage>–<lpage>250</lpage>.</citation></ref>
<ref id="bibr15-0961203313477900"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>BJ</given-names></name></person-group>. <article-title>Microangiopathic haemolytic anaemias in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>1028</fpage>–<lpage>1028</lpage>.</citation></ref>
<ref id="bibr16-0961203313477900"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>BJ</given-names></name><name><surname>Tueger</surname><given-names>S</given-names></name><name><surname>Pattison</surname><given-names>J</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name><name><surname>D'Cruz</surname><given-names>DP</given-names></name></person-group>. <article-title>Microangiopathic haemolytic anaemia secondary to lupus nephritis: An important differential diagnosis of thrombotic thrombocytopenic purpura</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>: <fpage>358</fpage>–<lpage>362</lpage>.</citation></ref>
<ref id="bibr17-0961203313477900"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muscal</surname><given-names>E</given-names></name><name><surname>Edwards</surname><given-names>RM</given-names></name><name><surname>Kearney</surname><given-names>DL</given-names></name><name><surname>Hicks</surname><given-names>JM</given-names></name><name><surname>Myones</surname><given-names>BL</given-names></name><name><surname>Teruya</surname><given-names>J</given-names></name></person-group>. <article-title>Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: Initial manifestation of childhood-onset systemic lupus erythematosus</article-title>. <source>Am J Clin Pathol</source> <year>2011</year>; <volume>135</volume>: <fpage>406</fpage>–<lpage>416</lpage>.</citation></ref>
<ref id="bibr18-0961203313477900"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Descombes</surname><given-names>E</given-names></name><name><surname>Droz</surname><given-names>D</given-names></name><name><surname>Drouet</surname><given-names>L</given-names></name><name><surname>Grunfeld</surname><given-names>JP</given-names></name><name><surname>Lesavre</surname><given-names>P</given-names></name></person-group>. <article-title>Renal vascular lesions in lupus nephritis</article-title>. <source>Medicine</source> <year>1997</year>; <volume>76</volume>: <fpage>355</fpage>–<lpage>368</lpage>.</citation></ref>
<ref id="bibr19-0961203313477900"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grishman</surname><given-names>E</given-names></name><name><surname>Venkataseshan</surname><given-names>VS</given-names></name></person-group>. <article-title>Vascular lesions in lupus nephritis</article-title>. <source>Modern Pathol</source> <year>1988</year>; <volume>1</volume>: <fpage>235</fpage>–<lpage>41</lpage>.</citation></ref>
<ref id="bibr20-0961203313477900"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manadan</surname><given-names>AM</given-names></name><name><surname>Harris</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Block</surname><given-names>JA</given-names></name></person-group>. <article-title>The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy</article-title>. <source>J Rheumatol</source> <year>2003</year>; <volume>30</volume>: <fpage>1227</fpage>–<lpage>1230</lpage>.</citation></ref>
<ref id="bibr21-0961203313477900"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>MH</given-names></name></person-group>. <article-title>Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome</article-title>. <source>Nephrol Dial Transplant</source> <year>2010</year>; <volume>25</volume>: <fpage>145</fpage>–<lpage>152</lpage>.</citation></ref>
<ref id="bibr22-0961203313477900"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gharbi</surname><given-names>C</given-names></name><name><surname>Bourry</surname><given-names>E</given-names></name><name><surname>Rouvier</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy</article-title>. <source>Clin Exp Nephrol</source> <year>2010</year>; <volume>14</volume>: <fpage>487</fpage>–<lpage>491</lpage>.</citation></ref>
<ref id="bibr23-0961203313477900"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>WX</given-names></name><name><surname>Liu</surname><given-names>ZZ</given-names></name><name><surname>Chen</surname><given-names>HP</given-names></name><name><surname>Zhang</surname><given-names>HT</given-names></name><name><surname>Li</surname><given-names>LS</given-names></name><name><surname>Liu</surname><given-names>ZH</given-names></name></person-group>. <article-title>Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1591</fpage>–<lpage>1598</lpage>.</citation></ref>
<ref id="bibr24-0961203313477900"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>GS</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name></person-group>. <article-title>Antiphospholipid syndrome in systemic lupus erythematosus</article-title>. <source>J Am Soc Nephrol</source> <year>2007</year>; <volume>18</volume>: <fpage>2461</fpage>–<lpage>2464</lpage>.</citation></ref>
<ref id="bibr25-0961203313477900"><label>25</label><citation citation-type="other"><comment>Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. <italic>J Am Soc Nephrol</italic> 2002; 13: 42–52</comment>.</citation></ref>
<ref id="bibr26-0961203313477900"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farrugia</surname><given-names>E</given-names></name><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Gastineau</surname><given-names>D</given-names></name><name><surname>Michet</surname><given-names>CJ</given-names></name><name><surname>Holley</surname><given-names>KE</given-names></name></person-group>. <article-title>Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study</article-title>. <source>Am J Kidney Dis</source> <year>1992</year>; <volume>20</volume>: <fpage>463</fpage>–<lpage>471</lpage>.</citation></ref>
<ref id="bibr27-0961203313477900"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughson</surname><given-names>MD</given-names></name><name><surname>Nadasdy</surname><given-names>T</given-names></name><name><surname>McCarty</surname><given-names>GA</given-names></name><name><surname>Sholer</surname><given-names>C</given-names></name><name><surname>Min</surname><given-names>KW</given-names></name><name><surname>Silva</surname><given-names>F</given-names></name></person-group>. <article-title>Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome</article-title>. <source>Am J Kidney Dis</source> <year>1992</year>; <volume>20</volume>: <fpage>150</fpage>–<lpage>158</lpage>.</citation></ref>
<ref id="bibr28-0961203313477900"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bridoux</surname><given-names>F</given-names></name><name><surname>Vrtovsnik</surname><given-names>F</given-names></name><name><surname>Noel</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival</article-title>. <source>Nephrol Dial Transplant</source> <year>1998</year>; <volume>13</volume>: <fpage>298</fpage>–<lpage>304</lpage>.</citation></ref>
<ref id="bibr29-0961203313477900"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Ventura</surname><given-names>D</given-names></name><name><surname>Riva</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis</article-title>. <source>Am J Kidney Dis</source> <year>2004</year>; <volume>43</volume>: <fpage>28</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr30-0961203313477900"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>AJ</given-names></name><name><surname>Swart</surname><given-names>RM</given-names></name><name><surname>te Boekhorst</surname><given-names>PA</given-names></name></person-group>. <article-title>Thrombopoietin-receptor agonists for immune thrombocytopenia</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>365</volume>: <fpage>2240</fpage>–<lpage>2241</lpage>.</citation></ref>
<ref id="bibr31-0961203313477900"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bussel</surname><given-names>JB</given-names></name><name><surname>Kuter</surname><given-names>DJ</given-names></name><name><surname>Pullarkat</surname><given-names>V</given-names></name><name><surname>Lyons</surname><given-names>RM</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Nichol</surname><given-names>JL</given-names></name></person-group>. <article-title>Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>: <fpage>2161</fpage>–<lpage>2171</lpage>.</citation></ref>
<ref id="bibr32-0961203313477900"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuker</surname><given-names>A</given-names></name></person-group>. <article-title>Toxicities of the thrombopoietic growth factors</article-title>. <source>Semin Hematol</source> <year>2010</year>; <volume>47</volume>: <fpage>289</fpage>–<lpage>298</lpage>.</citation></ref>
<ref id="bibr33-0961203313477900"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dultz</surname><given-names>G</given-names></name><name><surname>Kronenberger</surname><given-names>B</given-names></name><name><surname>Azizi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura</article-title>. <source>J Hepatol</source> <year>2011</year>; <volume>55</volume>: <fpage>229</fpage>–<lpage>232</lpage>.</citation></ref>
<ref id="bibr34-0961203313477900"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rayoo</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>van Gaal</surname><given-names>WJ</given-names></name></person-group>. <article-title>A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide–romiplostim</article-title>. <source>Heart Lung Circ</source> <year>2012</year>; <volume>21</volume>: <fpage>182</fpage>–<lpage>184</lpage>.</citation></ref>
<ref id="bibr35-0961203313477900"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gernsheimer</surname><given-names>TB</given-names></name><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Aledort</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)</article-title>. <source>J Thromb Haemost</source> <year>2010</year>; <volume>8</volume>: <fpage>1372</fpage>–<lpage>1382</lpage>.</citation></ref>
<ref id="bibr36-0961203313477900"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stasi</surname><given-names>R</given-names></name><name><surname>Bosworth</surname><given-names>J</given-names></name><name><surname>Rhodes</surname><given-names>E</given-names></name><name><surname>Shannon</surname><given-names>MS</given-names></name><name><surname>Willis</surname><given-names>F</given-names></name><name><surname>Gordon-Smith</surname><given-names>EC</given-names></name></person-group>. <article-title>Thrombopoietic agents</article-title>. <source>Blood Rev</source> <year>2010</year>; <volume>24</volume>: <fpage>179</fpage>–<lpage>190</lpage>.</citation></ref>
<ref id="bibr37-0961203313477900"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>JA</given-names></name><name><surname>Erickson-Miller</surname><given-names>CL</given-names></name><name><surname>Aivado</surname><given-names>M</given-names></name><name><surname>Abboud</surname><given-names>M</given-names></name><name><surname>Pillarisetti</surname><given-names>K</given-names></name><name><surname>Toomey</surname><given-names>JR</given-names></name></person-group>. <article-title>Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function</article-title>. <source>Exp Hematol</source> <year>2009</year>; <volume>37</volume>: <fpage>1030</fpage>–<lpage>1037</lpage>.</citation></ref>
</ref-list>
</back>
</article>